MG
Therapeutic Areas
Veru Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Enobosarm (VERU-024, ostarine, GTx-024, MK-2866) | Prevention of muscle loss and augmentation of fat loss in sarcopenic obese/overweight patients receiving GLP-1 RA therapy for weight management | Phase 2b |
| Sabizabulin (VERU-111) | Slow progression or promote regression of atherosclerosis in patients with atherosclerotic coronary artery disease (CAD) | Phase 2 |
Leadership Team at Veru
MS
Mitchell Steiner, M.D., F.A.C.S.
Chairman, President, and Chief Executive Officer
HF
Harry Fisch, M.D., F.A.C.S.
Vice Chairman, Chief Corporate Officer
KG
K. Gary Barnette, Ph.D.
Chief Scientific Officer
GB
Gary Bird, Ph.D.
Executive Vice President, Quality and Regulatory Affairs
SF
Samuel Fisch
Executive Director, Investor Relations & Corporate Communications
KG
Kevin Gilbert, JD, CPA
Executive Vice President, Corporate Development
PG
Philip Greenberg
Executive Vice President, General Counsel
DR
Domingo Rodriguez, M.D.
Executive Vice President, Global Clinical Operations